These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 10220596)
1. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Statistical issues in cost-effectiveness analysis. DeLong ER; Simons T Am Heart J; 1999 May; 137(5):S47-50. PubMed ID: 10220596 [No Abstract] [Full Text] [Related]
2. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Terminology I would like to see disappear. Detsky AS Am Heart J; 1999 May; 137(5):S51-2. PubMed ID: 10220597 [No Abstract] [Full Text] [Related]
3. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. A survey of standards and guidelines for cost-effectiveness analysis in health care. Stewart A; Schmier JK; Luce BR Am Heart J; 1999 May; 137(5):S53-61. PubMed ID: 10220598 [No Abstract] [Full Text] [Related]
4. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of economic models in randomized clinical trials. Hlatky MA Am Heart J; 1999 May; 137(5):S41-6. PubMed ID: 10220595 [No Abstract] [Full Text] [Related]
5. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Evaluating the economic implications of cardiovascular therapeutics. Califf RM Am Heart J; 1999 May; 137(5):S35-7. PubMed ID: 10220593 [No Abstract] [Full Text] [Related]
6. Proceedings of a symposium: economics and cost-effectiveness in evaluating the value of cardiovascular therapies. What constitutes a useful health economic study for the pharmaceutical industry? Gagnon JP Am Heart J; 1999 May; 137(5):S62-6. PubMed ID: 10220599 [No Abstract] [Full Text] [Related]
7. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of government agencies regarding cost-effectiveness claims: FDA perspective. Temple R Am Heart J; 1999 May; 137(5):S75-7. PubMed ID: 10220602 [No Abstract] [Full Text] [Related]
8. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Product labeling and pharmacoeconomic information. Morris LA Am Heart J; 1999 May; 137(5):S78-80. PubMed ID: 10220603 [No Abstract] [Full Text] [Related]
9. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Economics and cost-effectiveness in evaluating the value of cardiovascular therapy: lipid-lowering therapies--an industry perspective. Jackson JD Am Heart J; 1999 May; 137(5):S105-10. PubMed ID: 10220609 [No Abstract] [Full Text] [Related]
10. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Lipid-lowering drugs, cost-effectiveness data, and the formulary system: a health systems perspective. Kessler JM Am Heart J; 1999 May; 137(5):S111-4. PubMed ID: 10220610 [No Abstract] [Full Text] [Related]
12. The cost effectiveness of cardiovascular medicines. Hay J Curr Atheroscler Rep; 2005 Mar; 7(2):79-80. PubMed ID: 15727719 [No Abstract] [Full Text] [Related]
13. The cost-effectiveness of cardiovascular medicine: victims of our own success? Vardas PE Hellenic J Cardiol; 2013; 54(2):155-6. PubMed ID: 23557621 [No Abstract] [Full Text] [Related]
14. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Health system perspective regarding glycoprotein IIb/IIIa inhibitor therapy. Schrogie JJ Am Heart J; 1999 May; 137(5):S126-8. PubMed ID: 10220614 [No Abstract] [Full Text] [Related]
15. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies: a health system perspective on thrombolytic therapy for acute myocardial infarction. Lewandowski CA; Kahler J Am Heart J; 1999 May; 137(5):S94-6. PubMed ID: 10220607 [No Abstract] [Full Text] [Related]
16. Economics and Cost-Effectiveness in Evaluating the Value of Cardiovascular Therapies. Proceedings of a symposium. St. Petersburg, Florida, USA. April 17-20, 1997. Am Heart J; 1999 May; 137(5):S35-144. PubMed ID: 10366362 [No Abstract] [Full Text] [Related]
17. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. Muszbek N; Brixner D; Benedict A; Keskinaslan A; Khan ZM Int J Clin Pract; 2008 Feb; 62(2):338-51. PubMed ID: 18199282 [TBL] [Abstract][Full Text] [Related]
18. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Fundamentals of economic analysis. Mark DB; Simons TA Am Heart J; 1999 May; 137(5):S38-40. PubMed ID: 10220594 [No Abstract] [Full Text] [Related]
19. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. What constitutes a useful economic study? The health systems perspective. Lee TH Am Heart J; 1999 May; 137(5):S67-70. PubMed ID: 10220600 [No Abstract] [Full Text] [Related]
20. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data. Mark DB; Simons TA Am Heart J; 1999 May; 137(5):S123-5. PubMed ID: 10220613 [No Abstract] [Full Text] [Related] [Next] [New Search]